arginine has been researched along with Coronary Thrombosis in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 11 (52.38) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Curtis, BR; Erdil, RM; Gilyard, SN; Knelson, EH; Leaf, RK; Malhotra, R; Puram, RV; Ranganathan, R; Van Beuningen, AM; Wallwork, R; Weber, BN | 1 |
| Buszman, P; Czerwiński, W; Dębiński, M; Kondys, M; Zurek, P | 1 |
| Kawamura, M; Masai, T; Matsue, H; Yoshikawa, Y | 1 |
| Higuma, N; Honsako, A; Miida, T; Oda, H; Sakai, K; Takahashi, K | 1 |
| Satler, LF | 1 |
| Lentz, SR | 1 |
| Akhtar, S; Buja, LM; Casscells, W; Golino, P; Ober, JC; Scott-Burden, T; Willerson, JT; Yao, SK | 1 |
| Hori, M; Kamada, T; Kondo, H; Mano, T; Masuyama, T; Nagano, R; Naito, J; Tanouchi, J; Yamamoto, K | 1 |
| Adachi, K; Koide, M; Matsuo, T; Miki, T; Mizutani, K; Ohga, N; Sakamoto, S; Suzuki, S | 1 |
| Fitzgerald, D; Murphy, N | 1 |
| Aoki, N; Fujimori, Y; Kawai, K; Nakamura, F; Omata, M; Sakamoto, Y; Tomaru, T; Uchida, Y | 1 |
| Aoki, N; Nakamura, F; Omata, M; Sakamoto, Y; Tomaru, T; Uchida, Y | 1 |
| Crowley, JJ; Kruse, KR; Millare, DS; Phillips, HR; Santos, RM; Stack, RS; Tanguay, JF; Zidar, JP | 1 |
| Armstrong, PW; Choy, JB | 1 |
| Levi, M; Moons, AH; Peters, RJ | 1 |
| Chew, D; Reginelli, JP | 1 |
| Wittkowsky, AK | 1 |
| Tomoda, H | 1 |
| Collen, D; Fallon, JT; Gold, HK; Guerrero, JL; Holt, R; Jang, IK; Leinbach, RC; Yaoita, H; Yasuda, T | 1 |
| Chesebro, JH; Fuster, V | 1 |
| Fitzgerald, DJ; Fitzgerald, GA | 1 |
6 review(s) available for arginine and Coronary Thrombosis
| Article | Year |
|---|---|
Mechanisms of homocysteine-induced atherothrombosis.
Topics: Animals; Apolipoproteins E; Apoptosis; Arginine; Atherosclerosis; Coronary Thrombosis; Cysteine; Disease Models, Animal; Endothelium, Vascular; Homocysteine; Humans; Hyperhomocysteinemia; Inflammation; Methionine; Mice; Models, Biological; Nitric Oxide; Oxidative Stress; Oxygen; Phenotype; Signal Transduction | 2005 |
Argatroban: a synthetic thrombin inhibitor of low relative molecular mass.
Topics: Animals; Antithrombins; Arginine; Coronary Thrombosis; Humans; Pipecolic Acids; Sulfonamides | 1996 |
Anticoagulant therapy in unstable angina.
Topics: Angina, Unstable; Anticoagulants; Antithrombins; Arginine; Clinical Trials as Topic; Coronary Thrombosis; Disease Progression; Heparin; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Warfarin | 1999 |
Tissue factor and coronary artery disease.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Anticoagulants; Arginine; Aspirin; Coronary Artery Disease; Coronary Thrombosis; Cyclosporine; Endothelium, Vascular; Factor VIIa; Heparin, Low-Molecular-Weight; Hirudin Therapy; Humans; Hypolipidemic Agents; Leukocytes, Mononuclear; Muscle, Smooth, Vascular; Recombinant Proteins; Thrombin; Thromboplastin | 2002 |
Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition.
Topics: Angioplasty, Balloon, Coronary; Arginine; Coronary Thrombosis; Drug Therapy, Combination; Fibrinolytic Agents; Hirudin Therapy; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Sulfonamides | 2002 |
The role of thrombin inhibition during percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Arginine; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Fibrinolytic Agents; Fondaparinux; Heparin; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sulfonamides; Thrombin | 2002 |
1 trial(s) available for arginine and Coronary Thrombosis
| Article | Year |
|---|---|
Effect of argatroban on thrombus formation during acute coronary occlusion after balloon angioplasty.
Topics: Angioplasty, Balloon, Coronary; Antithrombins; Arginine; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Pipecolic Acids; Sulfonamides; Thrombolytic Therapy; Urokinase-Type Plasminogen Activator | 1995 |
14 other study(ies) available for arginine and Coronary Thrombosis
| Article | Year |
|---|---|
Thrombocytopenia and Thromboses in Myocardial Infarction Associated with Eptifibatide-Dependent Activating Antiplatelet Antibodies.
Topics: Antigens, Human Platelet; Arginine; Aspirin; Autoantibodies; Combined Modality Therapy; Coronary Thrombosis; Drug Substitution; Drug Therapy, Combination; Eptifibatide; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pipecolic Acids; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Transfusion; Purpura, Thrombocytopenic, Idiopathic; Shock, Cardiogenic; ST Elevation Myocardial Infarction; Stents; Sulfonamides; Thrombectomy; Thrombolytic Therapy; Thrombosis; Ticagrelor; Warfarin | 2020 |
[Acute myocardial infarction with simultaneous occlusions of two coronary arteries in a 44 year-old man].
Topics: Adult; Arginine; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Dietary Supplements; Electrocardiography; Humans; Male; Myocardial Infarction | 2013 |
Serious acute coronary thrombosis associated with heparin-induced thrombocytopenia in off-pump coronary artery bypass grafting.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Atherectomy, Coronary; Coronary Angiography; Coronary Artery Bypass, Off-Pump; Coronary Thrombosis; Female; Graft Occlusion, Vascular; Heparin; Humans; Pipecolic Acids; Stents; Sulfonamides; Thrombocytopenia; Time Factors; Treatment Outcome | 2010 |
Obstinate thrombosis during percutaneous coronary intervention in a case with heparin-induced thrombocytopenia with thrombosis syndrome successfully treated by argatroban anticoagulant therapy.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Cardiac Catheterization; Coronary Stenosis; Coronary Thrombosis; Follow-Up Studies; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Pipecolic Acids; Radiography; Risk Assessment; Sulfonamides; Syndrome; Thrombocytopenia; Treatment Outcome | 2003 |
Direct thrombin inhibitors during PCI.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Coronary Stenosis; Coronary Thrombosis; Follow-Up Studies; Heparin; Humans; Myocardial Infarction; Pipecolic Acids; Radiography; Risk Assessment; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2003 |
Endogenous and exogenous nitric oxide protect against intracoronary thrombosis and reocclusion after thrombolysis.
Topics: Animals; Arginine; Coronary Circulation; Coronary Thrombosis; Dogs; Electric Stimulation; Hematocrit; Nitric Oxide; Nitrites; Nitroarginine; Nitroprusside; Platelet Aggregation; Recurrence; Thrombolytic Therapy; Whole Blood Coagulation Time | 1995 |
Basal release of endothelium-derived nitric oxide plays an important role in the prevention of afterload mismatch in acute left ventricular dysfunction.
Topics: Acute Disease; Analysis of Variance; Animals; Arginine; Blood Pressure Determination; Coronary Thrombosis; Dogs; Echocardiography; Endothelium, Vascular; Enzyme Inhibitors; Hemodynamics; Microspheres; Nitric Oxide; omega-N-Methylarginine; Time Factors; Ventricular Dysfunction, Left | 1995 |
Induction of thrombolysis and prevention of thrombus formation by local drug delivery with a double-occlusion balloon catheter.
Topics: Angioscopy; Animals; Anticoagulants; Antithrombins; Arginine; Catheterization; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Heparin; Injections, Intralesional; Pipecolic Acids; Plasminogen Activators; Sulfonamides; Thrombolytic Therapy; Treatment Outcome | 1996 |
Local treatment with an antithrombotic drug reduces thrombus size in coronary and peripheral thrombosed arteries.
Topics: Angioscopy; Animals; Antithrombins; Arginine; Batroxobin; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heparin; Infusions, Intravenous; Injections, Intralesional; Pipecolic Acids; Reference Values; Sulfonamides; Treatment Outcome | 1996 |
Local drug delivery of argatroban from a polymeric-metallic composite stent reduces platelet deposition in a swine coronary model.
Topics: Animals; Antithrombins; Arginine; Blood Platelets; Coronary Thrombosis; Coronary Vessels; Indium Radioisotopes; Metals; Pipecolic Acids; Polymers; Random Allocation; Stents; Sulfonamides; Swine | 1999 |
Experimental evaluation of coronary thrombodynamics and effects of pharmacological interventions in acute coronary syndromes.
Topics: Animals; Antithrombins; Arginine; Coronary Circulation; Coronary Thrombosis; Dogs; Heparin; Myocardial Infarction; Pipecolic Acids; Sulfonamides; Thiophenes; Thrombolytic Therapy; Thromboxane-A Synthase; Urokinase-Type Plasminogen Activator | 1992 |
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation
Topics: Animals; Antibodies, Monoclonal; Antithrombins; Arginine; Aspirin; Coronary Circulation; Coronary Disease; Coronary Thrombosis; Dogs; Pipecolic Acids; Platelet Membrane Glycoproteins; Recurrence; Sulfonamides; Thrombolytic Therapy; Tissue Plasminogen Activator; Vascular Patency | 1990 |
Reperfusion, specific thrombin inhibition and reocclusion after thrombolysis.
Topics: Animals; Antibodies, Monoclonal; Antithrombins; Arginine; Coronary Disease; Coronary Thrombosis; Dogs; Pipecolic Acids; Platelet Membrane Glycoproteins; Recurrence; Sulfonamides; Thrombolytic Therapy; Tissue Plasminogen Activator | 1990 |
Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.
Topics: Animals; Antithrombins; Arginine; Coronary Disease; Coronary Thrombosis; Disease Models, Animal; Dogs; Phospholipases; Phospholipases A; Pipecolic Acids; Platelet Aggregation; Reperfusion; Sulfonamides; Thrombin; Tissue Plasminogen Activator | 1989 |